The FDA assessed the security and performance of atidarsagene autotemcel based on information from 37 young children who acquired atidarsagene autotemcel in two single-arm, open up-label clinical trials As well as in an expanded entry application.[seven] Kids who been given remedy with atidarsagene autotemcel were being when compared to untreated k